Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting | Zendy

Wolfgang Derer | Zendy; Elliot S. Barnathan | Zendy; Erdal Şafak | Zendy; Prasheen Agarwal | Zendy; Harald Heidecke | Zendy; Martin Möckel | Zendy; Michael Groß | Zendy; Cemil Oezcelik | Zendy; Rainer Dietz | Zendy; Ralf Dechend | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting

Author(s) -

Wolfgang Derer,

Elliot S. Barnathan,

Erdal Şafak,

Prasheen Agarwal,

Harald Heidecke,

Martin Möckel,

Michael Groß,

Cemil Oezcelik,

Rainer Dietz,

Ralf Dechend

Publication year - 2008

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.108.795799

Subject(s) - medicine , vitronectin , myocardial infarction , abciximab , cardiology , adverse effect , clinical endpoint , gastroenterology , randomized controlled trial , conventional pci , receptor , integrin

Vitronectin is a multifunctional protein with a multiple binding domain that interacts with a variety of plasma and cell proteins. Vitronectin binds multiple ligands, including the soluble vitronectin receptor. Abciximab binds equally well to soluble vitronectin receptor and glycoprotein IIb/IIIa, because both share the beta(3) subunit. We tested whether vitronectin concentrations correlate with adverse outcomes in acute coronary syndrome patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research